Precision BioSciences, Inc. (DTIL) Discusses ARCUS Platform Progress and ELIMINATE-B Clinical Trial Update for Chronic Hepatitis B Transcript
Source: SeekingAlpha
2025-11-11 16:11:34 ET
Precision BioSciences, Inc. (DTIL) Discusses ARCUS Platform Progress and ELIMINATE-B Clinical Trial Update for Chronic Hepatitis B November 11, 2025 8:00 AM EST...
Read the full article on Seeking Alpha
For further details see:
Precision BioSciences, Inc. (DTIL) Discusses ARCUS Platform Progress and ELIMINATE-B Clinical Trial Update for Chronic Hepatitis B Transcript
Precision BioSciences Inc.
NASDAQ: DTIL
DTIL Trading
-3.55% G/L:
$4.48 Last:
43,862 Volume:
$4.49 Open:
DTIL Latest News
March 02, 2026 07:01:00 am
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
February 18, 2026 07:01:00 am
Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
DTIL Stock Data
$86,782,150
21,981,758
2%
17
N/A
Biotechnology & Life Sciences
Healthcare
US
Durham
